Dinesh Patel
Net worth: 52 M $ as of 31/05/2026
Net worth: 52 M $ as of 31/05/2026
Dinesh V.
Patel was the founder of Miikana Therapeutics, Inc., founded in 2003, where the title held was President & Chief Executive Officer from 2003 to 2005.
Current jobs include President, Chief Executive Officer & Director at Protagonist Pty Ltd. since 2013, President, Chief Executive Officer & Director at Protagonist Therapeutics, Inc. since 2019, and Independent Director at Sai Life Sciences Ltd. starting in 2025.
Former jobs include President & Chief Executive Officer at Arête Therapeutics, Inc. from 2006 to 2008, Chemistry Director at Affymax, Inc. from 1993 to 1996, Medicinal Chemist at Bristol Myers Squibb Co. from 1985 to 1993, and Senior Vice President-Licensing & Drug Discovery at Vicuron Pharmaceuticals LLC from 1996 to 2003.
Education includes a doctorate from Rutgers State University of New Jersey and an undergraduate degree from Sardar Patel University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 12/05/2026 | 523,478 ( 0.81% ) | 52 M $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| PROTAGONIST THERAPEUTICS, INC. | Chief Executive Officer | 01/12/2008 |
| SAI LIFE SCIENCES LIMITED | Director/Board Member | 24/03/2025 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Chief Executive Officer | 06/07/2009 |
| Companies | Position | End |
|---|---|---|
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops and commercializes molecule drugs to treat cardiovascular diseases | Chief Executive Officer | 01/01/2008 |
Miikana Therapeutics, Inc.
Miikana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of cancer and inflammatory diseases | Chief Executive Officer | 01/01/2005 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01/01/2003 |
| AFFYMAX, INC. | Corporate Officer/Principal | 01/01/1996 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/1993 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 10 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Miikana Therapeutics, Inc.
Miikana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of cancer and inflammatory diseases | Health Technology |
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops and commercializes molecule drugs to treat cardiovascular diseases | Health Technology |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Health Technology |
Affymax, Inc.
Affymax, Inc. BiotechnologyHealth Technology Develops and distributes pharmaceutical products | Health Technology |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sardar Patel University
Sardar Patel University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sai Life Sciences Ltd.
Sai Life Sciences Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in contract research and manufacturing activities for pharmaceutical & biotechnology industries | Commercial Services |
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures peptide based therapeutic products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions